American Society of Clinical Oncology
225 Reinekers Lane
Suite 650
Alexandria
Virginia
22314
United States
Tel: 703-299-0150
Fax: 703-299-1044
Website: http://www.asco.org/
Email: asco@asco.org
2086 articles with American Society of Clinical Oncology
-
Well-known for its neurological drug development programs, Alkermes has firmly planted its flag as an oncology company at ASCO. Alkermes Head of Oncology Jessicca Rege spoke with BioSpace.
-
Primary seven-year data from Janssen's (Johnson & Johnson) Phase III trial of Imbruvica (ibrutinib) in lymphoma demonstrated positive survival outcomes.
-
Gilead Sciences shared what seemed to be good news regarding Trodelvy in HR+/HER2- breast cancer at the 2022 American Society of Clinical Oncology's annual meeting.
-
Data presented at the ASCO meeting this weekend show that treatment with Enhertu demonstrated a 49% improvement in median overall survival by more than six months.
-
Four life sciences companies posted previews of their respective programs ahead of the American Society of Clinical Oncology (ASCO) annual meeting on June 5, 2022.
-
Zymeworks increased its stake in the company to 6.9%, slightly under 4 million shares, and options with shares popped 13% after the original bid and are up another 10%.
-
New Data Showcases How Amgen Is Advancing All Angles of Cancer Care Through Innovative Oncology Portfolio and Pipeline at ASCO 2022
5/26/2022
Amgen will present new data from across its broad oncology innovative medicines and biosimilars portfolio and robust pipeline at the American Society of Clinical Oncology Annual Meeting from June 3-7 in Chicago and virtually.
-
The American Society of Clinical Oncology and the Association of Community Cancer Centers are combining their efforts to increase racial and ethnic diversity in clinical trials.
-
Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
2/1/2022
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium, taking place in San Francisco and virtually from February 17-19.
-
Alkermes to Present Data on Nemvaleukin Alfa at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
1/18/2022
Alkermes plc announced plans to present a poster related to nemvaleukin alfa, the company's novel, investigational, engineered interleukin-2 variant immunotherapy, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, taking place Jan. 20-22, 2022.
-
In an interview with BioSpace, CEO Victoria Richon expressed her excitement about investor support and developing novel, first-in-class treatments.
-
The FDA granted it to Lu-PSMA-617, an investigational radioligand therapy to treat metastatic castration-resistant prostate cancer.
-
Novartis flexed its clinical muscles over the weekend, announcing results from multiple studies including different types of cancer and kidney disease.
-
Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting
6/4/2021
Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients
-
With the 2021 American Society of Clinical Oncology Annual Meeting now in high gear, there is plenty of news. Here’s a look at just some of the most recent stories.
-
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021
6/2/2021
ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral administration at the 2021 American Society of Clinical Oncology Annual Meeting on June 4-8, 2021 for the first time.
-
Lilly Announces Details of Presentations at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
5/19/2021
New data from across Eli Lilly and Company's oncology portfolio will be presented at the 2021 American Society of Clinical Oncology Annual Meeting, held June 4-8, 2021.
-
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial
5/19/2021
Adaptimmune Therapeutics plc, a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel, at the American Society of Clinical Oncology congress.
-
The FDA further delays Iovance’s filing for its TIL therapy as it requests additional data on the treatment’s potency assays.
-
Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer
5/19/2021
Amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), achieved an objective response rate of 34% and a clinical benefit rate of 74% in Phase 1 study (AMEERA-1) in combination with palbociclib